Cargando…

STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer

BACKGROUND: The management of unresectable metastatic colorectal cancer (mCRC) is a comprehensive treatment strategy involving several lines of therapy, maintenance, salvage surgery, and treatment-free intervals. Besides chemotherapy (fluoropyrimidine, oxaliplatin, irinotecan), molecular-targeted ag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chibaudel, Benoist, Bonnetain, Franck, Tournigand, Christophe, de Larauze, Marine Hug, de Gramont, Armand, Laurent-Puig, Pierre, Paget, Jérôme, Hadengue, Alexandra, Notelet, Dominique, Benetkiewicz, Magdalena, André, Thierry, de Gramont, Aimery
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4490616/ https://www.ncbi.nlm.nih.gov/pubmed/26141683 http://dx.doi.org/10.1186/s12885-015-1503-7

Ejemplares similares

Could baseline health-related quality of life (QoL) predict overall survival in metastatic colorectal cancer? The results of the GERCOR OPTIMOX 1 study
por: Diouf, Momar, et al.
Publicado: (2014)

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial
por: Hamidou, Zeinab, et al.
Publicado: (2016)

Induction therapy with cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (ETPF) in patients with resectable nonmetastatic stage III or IV squamous cell carcinoma of the oropharynx. A GERCOR phase II ECHO-07 study
por: Chibaudel, Benoist, et al.
Publicado: (2015)

PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM‐398) or irinotecan with leucovorin/5‐fluorouracil as second‐line therapy in metastatic colorectal cancer
por: Chibaudel, Benoist, et al.
Publicado: (2016)

A randomized phase II study of weekly nab-paclitaxel plus gemcitabine or simplified LV5FU2 as first-line therapy in patients with metastatic pancreatic cancer: the AFUGEM GERCOR trial
por: Bachet, Jean-Baptiste, et al.
Publicado: (2015)

Improving Outcomes in Patients with CRC: The Role of Patient Reported Outcomes—An ESDO Report
por: Van Cutsem, Eric, et al.
Publicado: (2017)

MAINTENANCE HORMONAL TREATMENT IMPROVES PROGRESSION FREE SURVIVAL AFTER A FIRST LINE CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST CANCER
por: Dufresne, Armelle, et al.
Publicado: (2008)

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer
por: Carola, Candice, et al.
Publicado: (2018)

New curative approach using embolization followed by moderate-dose radiotherapy after surgical failure for large right heart metastasis
por: Delanian, Sylvie, et al.
Publicado: (2021)

Impact on health‐related quality of life deterioration‐free survival of a first‐line therapy combining nab‐paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil for patients with metastatic pancreatic cancer: Results of the randomized phase II AFUGEM GERCOR clinical trial
por: Charton, Emilie, et al.
Publicado: (2019)

RECIST and iRECIST criteria for the evaluation of nivolumab plus ipilimumab in patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the GERCOR NIPICOL phase II study
por: Cohen, Romain, et al.
Publicado: (2020)

Novel TGF-β inhibitors ready for prime time in onco-immunology
por: de Gramont, Armand, et al.
Publicado: (2016)

Rationale and design of the Adapted Physical Activity in advanced Pancreatic Cancer patients (APACaP) GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie) trial: study protocol for a randomized controlled trial
por: Neuzillet, Cindy, et al.
Publicado: (2015)

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)
por: Vernerey, Dewi, et al.
Publicado: (2016)

Intrinsic bevacizumab resistance is associated with prolonged activation of autocrine VEGF signaling and hypoxia tolerance in colorectal cancer cells and can be overcome by nintedanib, a small molecule angiokinase inhibitor
por: Mésange, Paul, et al.
Publicado: (2014)

Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
por: Anota, Amélie, et al.
Publicado: (2013)

Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM
por: Bouattour, Mohamed, et al.
Publicado: (2016)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
por: Kim, Stefano, et al.
Publicado: (2017)

Kant et la question de l'affectivité : lecture de la troisième critique
por: Gramont, Jérôme de
Publicado: (1996)

Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis
por: Innominato, Pasquale F., et al.
Publicado: (2022)

Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation status
por: Marijon, Hélène, et al.
Publicado: (2021)

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study
por: André, Thierry, et al.
Publicado: (2023)

Association of post-operative CEA with survival and oxaliplatin benefit in patients with stage II colon cancer: a post hoc analysis of the MOSAIC trial
por: Auclin, Edouard, et al.
Publicado: (2019)

Memoirs of the court of Charles II
por: Gramont, Philibert, comte de, 1621-1707
Publicado: (1910)

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study
por: Evrard, Diane, et al.
Publicado: (2022)

Targeting cancer cell metabolism in pancreatic adenocarcinoma
por: Cohen, Romain, et al.
Publicado: (2015)

Bevacizumab-based first-line chemotherapy in elderly patients with metastatic colorectal cancer: an individual patient data based meta-analysis
por: Koch, Christine, et al.
Publicado: (2017)

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas
por: Neuzillet, Cindy, et al.
Publicado: (2013)

Erratum to: Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty
por: Vernerey, Dewi, et al.
Publicado: (2016)

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty
por: Vernerey, Dewi, et al.
Publicado: (2016)

ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
por: Zaanan, Aziz, et al.
Publicado: (2014)

Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer: A Secondary Analysis of the AVANT Trial
por: Chibaudel, Benoist, et al.
Publicado: (2020)

Immune microenvironment in patients with mismatch‐repair‐proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study
por: Jary, Marine, et al.
Publicado: (2022)

Prohibitin (PHB) expression is associated with aggressiveness in DLBCL and flavagline-mediated inhibition of cytoplasmic PHB functions induces anti-tumor effects
por: Bentayeb, Hafidha, et al.
Publicado: (2019)

Analysis of neurosensory adverse events induced by FOLFOX4 treatment in colorectal cancer patients: a comparison between two Asian studies and four Western studies
por: Sugihara, Kenichi, et al.
Publicado: (2012)

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial
por: Kim, Stefano, et al.
Publicado: (2020)

« COVID long » : une opportunité pour approcher la complexité des syndromes fonctionnels post-infectieux
por: Cathébras, P., et al.
Publicado: (2021)

Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound
por: Serova, Maria, et al.
Publicado: (2013)

Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients
por: Serova, Maria, et al.
Publicado: (2015)

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer
por: Louvet, C., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_766226nsd7dei283pfflv1kfqj